Pfizer Completes Acquisition of Seagen
Further establishes Pfizer as a leading oncology company poised to accelerate the next generation of breakthrough treatments for…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
15 Dec 23
Further establishes Pfizer as a leading oncology company poised to accelerate the next generation of breakthrough treatments for…
14 Dec 23
The latest designation comes after Investigational New Drug (IND) clearance for KYV-101 for use in Kyverna's KYSA-6 Phase…
14 Dec 23
The state-of-the-art preclinical laboratory solidifies Veranex's commitment to expanding its existing preclinical footprint and deepening its therapeutic expertise
13 Dec 23
Pfizer also announced changes in its commercial organisation to incorporate Seagen by creating a new end-to-end business arm…
13 Dec 23
Submission supported by positive results of a Phase III study showing immune response and safety in adults aged…
12 Dec 23
The Commission claimed that the deal, which could be worth up to $755m, would destroy a startup rival…
12 Dec 23
The new partnership aims to bolster and broaden CancerLinQ's use of real-world data, analytics, AI, and other technologies,…
12 Dec 23
Submissions based on positive data from the Phase 3 BASIS trial, which were presented this past weekend at…
11 Dec 23
Casgevy is a genome-edited cellular therapy that consists of autologous CD34+ HSCs edited by CRISPR/Cas9 technology, while Lyfgenia…
11 Dec 23
The EC approval was based on findings from cohort A of the Phase 2 MagnetisMM-3 study in which…